肿瘤细胞治疗研究
英文原题：Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.
Development and biomarkers of CD20/CD3 bispecific antibodies in diffuse large B-cell lymphoma.
复发性/难治性弥漫大B细胞淋巴瘤的化疗疗效仍然不足。
复发/难治性弥漫大B细胞淋巴瘤的化疗疗效仍不理想。近年来，T细胞衔接疗法的进展，包括CAR-T 细胞疗法和双特异性抗体（BsAbs），旨在克服化疗耐药。靶向CD20/CD3的BsAbs，如epcoritamab、glofitamab、mosunetuzumab和odronextamab，正迅速推进至广泛临床应用。本综述总结了各BsAb的临床疗效，并强调需要谨慎管理不良事件，如细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。尽管单药治疗仍是标准方案，临床试验正在探索更早线使用和联合策略以进一步提高疗效。特别关注了预测缓解的生物标志物和耐药机制，包括靶抗原丢失、肿瘤组织学、既往治疗、瘤内和外周T细胞状态，以及微小残留病监测的新兴作用。
The efficacy of chemotherapy for relapsed/refractory diffuse large B-cell lymphoma remains inadequate. Recent advances in T-cell engaging therapies, including chimeric antigen receptor T-cell therapy and bispecific antibodies (BsAbs), aim to overcome chemotherapy resistance. BsAbs targeting CD20/CD3, such as epcoritamab, glofitamab, mosunetuzumab, and odronextamab, are rapidly progressing toward widespread clinical application. This review summarizes the clinical efficacy of each BsAb and highlights the need for careful management of adverse events, such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. Although monotherapy remains the standard approach, clinical trials are exploring earlier-line use and combination strategies to further enhance outcomes. Particular attention is given to predictive biomarkers of response and mechanisms of resistance, including target antigen loss, tumor histology, prior therapies, intratumoral and peripheral T-cell status, and the emerging role of minimal residual disease monitoring.
MEMBER ACCOUNT
登录成功会直接打开下一页。
